US Pharma MarketingOwkin, a company that develops AI tools for drug discovery and pharmaceutical research, has entered into a three-year licensing agreement with pharma giant AstraZeneca for K Pro, Owkin's AI Scientist platform designed for pharmaceutical research and decision support.
Owkin, AstraZeneca expand collaboration on AI-driven drug research tools
The partners enter a three-year agreement to deploy AI agents via Owkin's K Pro platform to accelerate research, competitive intelligence and drug development decision-making. Owkin , a company that develops AI tools for drug discovery and pharmaceutical research, has entered into a three-year licensing agreement with pharma giant AstraZeneca for K Pro, Owkin's AI Scientist platform designed for pharmaceutical research and decision support. As part of the agreement, Owkin will develop AI agents for AstraZeneca teams that will operate through the K Pro platform and integrate into the company's existing IT infrastructure and workflows. The agents are designed to help…
Source: MobiHealthNews